PsyBio Therapeutics Corp.
PSYBF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 6/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $50 | $1,563 | $1,535 | $0 |
| Gross Profit | -$50 | -$1,563 | -$1,535 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $390 | $623 | $55 | $0 |
| G&A Expenses | $3,947 | $8,898 | $992 | $0 |
| SG&A Expenses | $3,947 | $8,898 | $4,847 | $39 |
| Sales & Mktg Exp. | $0 | $0 | $3,855 | $0 |
| Other Operating Expenses | -$49 | -$2,041 | -$1 | $0 |
| Operating Expenses | $4,288 | $7,480 | $4,901 | $39 |
| Operating Income | -$4,338 | -$9,043 | -$6,436 | -$39 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$548 | -$1,976 | $0 | $23 |
| Pre-Tax Income | -$4,886 | -$11,019 | -$6,436 | -$16 |
| Tax Expense | $0 | $1,431 | $0 | $0 |
| Net Income | -$4,886 | -$11,019 | -$6,436 | -$16 |
| % Margin | – | – | – | – |
| EPS | -0.042 | -0.1 | -0.2 | 0 |
| % Growth | 58% | 50% | – | – |
| EPS Diluted | -0.042 | -0.1 | -0.2 | 0 |
| Weighted Avg Shares Out | 111,810 | 106,935 | 31,594 | 0 |
| Weighted Avg Shares Out Dil | 111,810 | 106,935 | 31,594 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $32 | $0 | $0 |
| Interest Expense | $21 | $0 | $0 | $0 |
| Depreciation & Amortization | $152 | $9,043 | $6,436 | $172 |
| EBITDA | -$4,526 | -$9,579 | $0 | $156 |
| % Margin | – | – | – | – |